Rifaximin CAS NO.80621-81-4

1.High quality and competetive price

1)We can offer COA Certificate and official Invoice.
2)We are manufacturer with own lab and factory, can provide high quality products with factory price. 
3)Products purity is test by our quality department strictly before sending, and you can also ask the third testing organization come and inspect, such as (SGS/ CTI/ ITS), only after your confirmation will we send it out to you.

2.Fast and safe delivery

1)Products can be arranged first time we receive your prepayment. Fixed service person are 7x24h for you to contact.
2) Secure and discreet shipment. Various transportation methods for your choice, like DHL/UPS/TNT/FedEx/SF-express/Sea/Train/Air

3.We have clients throughout the world

1) Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire. 
2) Market feedback and goods feedback will be appreciated, meeting customers' requirement is our responsibility. 
3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers. 

Rifaximin 80621-81-4

    

Function 

Intestinal infection, including acute and chronic intestinal infection, diarrhea, diarrhea, summer travelers and small intestine diarrhea conjunctivitis, and so on

Uses

Rifaximin is licensed by the U.S. Food and Drug Administration to treat traveler's diarrhea caused by E. coli.Clinical trials have shown that rifaximin is highly effective at preventing and treating traveler's diarrhea among travelers to Mexico, with fewside effects and low risk of developing antibiotic resistance.It is not effective against Campylobacter jejuni, and there is no evidence of efficacy against Shigella orSalmonella species.

It may be efficacious in relieving chronic functional symptoms of bloating and flatulence that are common in irritable bowel syndrome (IBS),especially IBS-D.

There was recently a pilot-study done on the efficacy of rifaximin as a means of treatment for rosacea, according to the study, induced by the co-presence of small intestinal bacterial overgrowth.

In the United States, rifaximin has orphan drug status for the treatment of hepatic encephalopathy.Although high-quality evidence is still lacking, rifaximin appears to be as effective as or more effective than other available treatments for hepatic encephalopathy (such as lactulose), is better tolerated, and may work faster. The drawbacks to rifaximin are increased cost and lack of robust clinical trials for HE without combination lactulose therapy.